ESSA Pharma

ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.

Earnings

Equities

News

Eurozone

Commodities

Markets

Trading Ideas

AAPL

CDXC

EPIX

LXRX

MYGN

PRLB

TILE

Crude Oil Moves Higher; Apple Shares Slide After Q4 Results

Amazon To Deploy AI-Powered Package Identifying Tech On 1000 Rivian Delivery Vans For Faster Deliveries

AMZN

Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results

Workers Manage to Secure Multiple Jobs at Once

ELAB

Dow Jumps 400 Points; US Adds 12,000 Jobs In October

ESSA Pharma Inc

Press Releases

EPIX Deadline: EPIX Investors Have Opportunity to Lead ESSA Pharma Inc. Securities Fraud Lawsuit

Legal

EPIX IMPORTANT DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ESSA Pharma Inc. Investors to Secure Counsel Before Important March 25 Deadline in Securities Class Action - EPIX

EPIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that ESSA Pharma Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

ESSA Pharma Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights – EPIX

The Gross Law Firm Reminds ESSA Pharma Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - EPIX

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA Pharma

ESSA Pharma Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; March 25, 2025 Deadline to file Lead Plaintiff Motion

EPIX Deadline Today: Rosen Law Firm Urges ESSA Pharma Inc. (NASDAQ: EPIX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

ESSA Pharma Inc. Class Action: Levi & Korsinsky Reminds ESSA Pharma Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - EPIX

ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Biomea Fusion

Cibus

Coherus Oncology

Climb Bio

Elutia

Forte Biosciences

IGM Biosciences

Immunic

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

IO Biotech

Invivyd

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Macrogenics

OKYO Pharma

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Pyxis Oncology

Quince Therapeutics

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Surrozen

TScan Therapeutics

XBiotech

Piper Sandler

Oppenheimer

Comments

ESSA Pharma

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell